VIR — Vir Biotechnology, Inc. stock price, charts and financials

QT72Vir Biotechnology, Inc.

Vir Biotechnology, Inc. (NASDAQ: VIR) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
8.88
+0.07+0.74%
OverviewShort InterestFilings
VIRQT72Vir Biotechnology, Inc.·NASDAQ
8.88+0.74%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
AUPH-2.40%$15.47MESO+4.89%$16.72ZBIO-1.46%$31.96GHRS-1.65%$29.77TSHA-1.45%$6.46STOK-1.65%$32.17ABCL+36.44%$9.46VRDN-3.25%$22.82
Snapshot
Index-P/E-EPS (ttm)-4.00Insider Own49.32%Shs Outstand168.65MPerf Week1.85%
Market Cap1.49BForward P/E-EPS next Y-2.47Insider Trans-0.31%Shs Float128.76MPerf Month-14.70%
Enterprise Value1.30BPEG-EPS next Q-Inst Own-Short Float14.33%Perf Quarter-4.85%
Income-253.03MP/S4.91EPS this Y53.09%Inst Trans-Short Ratio9.83Perf Half Y27.46%
Sales303.23MP/B1.51EPS next Y-31.39%ROA-20.72%Short Interest18.45MPerf YTD46.27%
Book/sh-P/C-EPS next 5Y-ROE-29.99%52W High11.75 -24.36%Perf Year73.62%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-23.89%52W Low4.19 112.02%Perf 3Y-37.18%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-65.05% 0.59%Gross Margin-Volatility5.76% 4.82%Perf 5Y-75.26%
Dividend TTM-EV/Sales4.29EPS Y/Y TTM18.28%Oper. Margin-88.97%ATR (14)0.47Perf 10Y-
Dividend Ex-Date-Quick Ratio6.04Sales Y/Y TTM-Profit Margin-83.00%RSI (14)43.44Recom2.17
Dividend Gr. 3/5Y-Current Ratio6.04EPS Q/Q3.41%SMA20-3.24%Beta1.58Target Price21.43
Payout0.00%Debt/Eq0.09Sales Q/Q-100.00%SMA50-5.06%Rel Volume0.89Prev Close8.82
Employees367LT Debt/Eq0.23EarningsNov 04SMA2008.34%Avg Volume1.86MPrice8.88
IPO DateOct 11, 2019Option/ShortYes / YesEPS/Sales Surpr.-790.05% -100.05%Net Debt/EBITDA0.76Volume1,663,112Change0.74%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-06-26ReiteratedMorgan StanleyOverweight$27 → $25
Jun-11-26ReiteratedMorgan StanleyOverweight$23 → $27
May-08-26ReiteratedMorgan StanleyOverweight$24 → $23
Mar-04-26ReiteratedHC Wainwright & Co.Buy$15 → $20
Feb-26-26ReiteratedLeerink PartnersOutperform$20
Feb-24-26ReiteratedRaymond James$12 → $19
Feb-24-26ReiteratedMorgan StanleyOverweight$20 → $24
Feb-24-26ReiteratedNeedhamBuy$35 → $18
Feb-24-26ReiteratedEvercore ISI GroupOutperform$18
Feb-17-26ReiteratedBarclaysOverweight$24 → $26
Latest News
Aug-06-26
Aug-06-2604:20AM
Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call Transcriptseekingalpha.com
03:05AM
Vir Biotechnology Q2 Earnings Call Highlightsmarketbeat.com
Aug-05-26
Aug-05-2609:36PM
Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimateszacks.com
04:15PM
Vir Biotechnology Q2 EPS $0.47 Beats $0.18 Estimate, Sales $238.946M Beat $216.456M EstimateBenzinga
04:05PM
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Resultsbusinesswire.com
Jul-24-26
Jul-24-2609:00AM
Vir Biotechnology Announces Chief Financial Officer Transitiongurufocus.com
Jul-22-26
Jul-22-2604:05PM
Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Resultsbusinesswire.com
Jul-16-26
Jul-16-2608:45AM
Vir Biotechnology: Multiple Catalysts In Hepatitis And Oncology Aheadseekingalpha.com
Jun-11-26
Jun-11-2608:30AM
Morgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $27Benzinga
Company

Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
FY 2017
12/31/2017
Total Revenue697486——————
Cost of Goods Sold Incl. D&A12479573——————
Gross Profit57-404-487——————
Selling, General and Administrative Excl. Other9200——————
Research and Development433506580——————
Other Operating Expense0-323-382——————
Operating Income-468-587-684——————
Interest Expense
000——————
Unusual Expense
—————————
Non-Operating Income (Expense)306456——————
Net Income Before Taxes-438-523-628——————
Income Taxes0-1-13——————
Consolidated Net Income-438-522-615——————
Net Income From Continuing Operations-438-522-615——————
Net Income-438-522-615——————
EPS (Recurring)-3.16-3.83-4.59——————
EPS (Basic, Before Extraordinaries)-3.16-3.83-4.59——————
EPS (Diluted)-3.16-3.83-4.59——————
EBITDA-426-509-642——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio12.1513.4915.67——————
Gross Margin82.61-545.95-566.28——————
Operating Margin-678.26-793.24-795.35——————
Net Margin-634.78-705.41-715.12——————
Shares Outstanding139136134——————
Market Capitalization8389981,348——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$12.11$9.90$7.69$5.47$3.26● Close Price0.00M3.18M6.35M9.53M12.71MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Napolitano JanetDirectorJun 01 '26Sale9.453,20030,24021,216Jun 02
Sabatini BrentSVP, Chief Accounting OfficerJun 01 '26Sale9.453793,58261,902Jun 02
SATO VICKI LDirectorMay 01 '26Sale10.0522,000221,0251,078,391May 04
De Backer MariannePresident and CEOApr 06 '26Sale9.1672,559664,350948,145Apr 07
SATO VICKI LDirectorApr 01 '26Sale9.0722,000199,6171,100,391Apr 02
Sabatini BrentSVP, Chief Accounting OfficerMar 23 '26Sale9.127,71170,32461,902Mar 24
SATO VICKI LDirectorMar 02 '26Sale9.5122,000209,1811,122,391Mar 03
de Verneuil VaninaEVP, General Counsel, Corp SecFeb 25 '26Sale9.8213,700134,534112,982Feb 26
Eisner MarkEVP and Chief Medical OfficerFeb 25 '26Sale9.821,88918,550154,024Feb 26
De Backer MarianneChief Executive OfficerFeb 24 '26Sale9.5314,762140,7201,020,704Feb 26
SATO VICKI LDirectorFeb 24 '26Option Exercise1.4942,37762,9301,186,768Feb 26
SATO VICKI LDirectorFeb 24 '26Sale9.7542,377413,3661,144,391Feb 26
Sabatini BrentSVP, Chief Accounting OfficerFeb 24 '26Sale9.531,43013,63269,613Feb 26
O'Byrne JasonEVP & Chief Financial OfficerFeb 24 '26Sale9.531,63415,576162,615Feb 26
Eisner MarkEVP and Chief Medical OfficerFeb 24 '26Sale9.531,61615,405155,913Feb 26
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.